Please login (Members) to view content or
(Nonmembers) this article.
0
No votes yet
Article

New Agents and Future Directions in Biotherapy

Patricia Sorokin
CJON 2002, 6(1), 19-24 DOI: 10.1188/02.CJON.19-24

Many new biotherapy agents to treat cancer are being studied as single agents and in combination with conventional cancer therapy, such as chemotherapy. These agents include the monoclonal antibodies, rituximab, trastuzumab, alemtuzumab and IMC-C225. Radioimmunotherapy, a type of biotherapy that combines a radioactive isotope with a monoclonal antibody, also is being studied and has shown promise in the treatment of lymphoma. A tyrosine kinase inhibitor. STI 571, has been approved recently by the U.S. Food and Drug Administration. Several vaccines as cancer treatment are currently under investigation. Other biotherapy agents being investigated include angiogenesis inhibitors, such as endostatin. antivascular endothelial cell growth factor and thalidomide, an agent that inhibits the formation of blood vessels that supply tumors.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or